Eflornithine

CHEMBL830 Phase 4 승인됨 Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

182.2 g/mol

LogP

-2.9

Phase

4

This drug works by blocking an enzyme that cancer cells and certain parasites need to grow and survive. It is used in the treatment of certain cancers and has also been studied for other conditions.

분자량

182.1700 g/mol

LogP

-2.90

TPSA

89.30 Å²

리핀스키 5의 법칙

통과

치료 영역

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Non-Small Cell Lung Cancer Melanoma Type 2 Diabetes Breast Cancer Prostate Cancer Colorectal Cancer

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D 구조

SVG PNG

Cite this structure

Embed this structure

SMILES

NCCCC(N)(C(=O)O)C(F)F

InChI

InChI=1S/C6H12F2N2O2/c7-4(8)6(10,5(11)12)2-1-3-9/h4H,1-3,9-10H2,(H,11,12)

Molecular Formula

C6H12F2N2O2

HBD / HBA

3 / 6

회전 가능 결합

5

무거운 원자

12

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

자주 묻는 질문

This drug works by blocking an enzyme that cancer cells and certain parasites need to grow and survive. It is used in the treatment of certain cancers and has also been studied for other conditions.

Yes, Eflornithine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL830. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 3009. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

환자 친화적 정보를 찾고 계신가요?

Eflornithine PillFYI에서

구조

핵심 데이터

분자식: C6H12F2N2O2
동의어: 3

외부 링크

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

의학적 면책조항

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.